Advertisement

Chinese Journal of Integrative Medicine

, Volume 24, Issue 6, pp 474–480 | Cite as

Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine

  • Huan-dong Zhao
  • Hong-juan Xie
  • Jian Li
  • Cai-ping Ren
  • Yu-xiang Chen
Review

Abstract

Multidrug resistance (MDR) is a major cause of cancer chemotherapy failure, and it is important to develop suitable reversal agents to overcome MDR. A majority of chemical reversal agents have acceptable reversal effects. However, the toxicity and adverse reactions associated with these agents restricts their clinical use. Chinese medicines (CMs) have lower toxicities and adverse reactions and are associated with multiple components, multiple targets and reduced toxicity. CMs have several advantages and could reverse MDR, decrease drug dosage, enhance patient compliance and increase efficacy. This review summarizes the current progress of CM reversal agents..

Keywords

tumor multidrug resistance reversal agents Chinese medicine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174–1184.PubMedGoogle Scholar
  2. 2.
    Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105–127.CrossRefPubMedGoogle Scholar
  3. 3.
    Hung TH, Chen CM, Tseng CP, Shen CJ, Wang HL, Choo KB, et al. FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells. Int J Biochem Cell Biol 2014;53:55–65.CrossRefPubMedGoogle Scholar
  4. 4.
    West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234–248.CrossRefPubMedGoogle Scholar
  5. 5.
    Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714–726.CrossRefPubMedGoogle Scholar
  6. 6.
    Lin LF, Wu MH, Pidugu VK, Ho IC, Su TL, Lee TC. P-glycoprotein attenuates DNA repair activity in multidrugresistant cells by acting through the Cbp-Csk-Src cascade. Oncotarget 2017;8:45072–45087.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Chao J, Dai Y, Verpoorte R, Lam W, Cheng YC. Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochem Pharmacol 2017;139:94–104.CrossRefPubMedGoogle Scholar
  8. 8.
    Li C, Sun BQ, Gai XD. Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours. Clin Transl Oncol 2014;16:593–598.CrossRefPubMedGoogle Scholar
  9. 9.
    Pan H, Lu LY, Wang XQ, Li BX, Kelly K, Lin HS. Gambogic acid induces cell apoptosis and inhibits MAPK pathway in PTEN-/-/p53-/-prostate cancer cells in vitro and ex vivo. Chin J Integr Med 2017;23:1–8.CrossRefGoogle Scholar
  10. 10.
    Wang X, Deng R, Lu Y, Xu Q, Yan M, Ye D, et al. Gambogic acid as a non-competitive inhibitor of ATPbinding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATPbinding cassette transporter B1 protein degradation. Basic Clin Pharmacol Toxicol 2013;112:25–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Tian L, Liu J, Chen BA, Cheng J, Ding JH, Wang S, et al. Reversal effect of gambogic acid on multidrug resistance of K562/A02 cell line. J Exp Hematol 2012;20:252–257.Google Scholar
  12. 12.
    Wen C, Huang L, Chen J, Lin M, Li W, Lu B, et al. Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. Int J Oncol 2015;47:1663–1671.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang C, Wang W, Wang C, Tang Y, Tian H. Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett 2015;10:2063–2066.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wang S, Yang Y, Wang Y, Chen M. Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance. Int J Pharm 2015;495:840–848.CrossRefPubMedGoogle Scholar
  15. 15.
    Fang X, Xu Y, Wang S, Wan J, He C, Chen M. Pluronic F68-linoleic acid nano-spheres mediated delivery of gambogic acid for cancer therapy. AAPS Pharm Sci Tech 2016;18:147–155.CrossRefGoogle Scholar
  16. 16.
    Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 2006;57:376–388.CrossRefPubMedGoogle Scholar
  17. 17.
    Meng SI, Zhao J, Li X, Tian JG, Li YG, Li JM. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Chin Med J 2013;126:4116–4123.Google Scholar
  18. 18.
    Dash TK, Konkimalla VB. Selection of P-glycoprotein inhibitor and formulation of combinational nanoformulation containing selected agent curcumin and DOX for reversal of resistance in K562 cells. Pharm Res 2017;34:1–10.CrossRefGoogle Scholar
  19. 19.
    Lu WD, Qin Y, Yang C, Li L, Fu ZX. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics (Sao Paulo) 2013;68:694–701.CrossRefGoogle Scholar
  20. 20.
    Revalde JL, Li Y, Hawkins BC, Rosengren RJ, Paxton JW. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. Biochem Pharmacol 2015;93:305–317.CrossRefPubMedGoogle Scholar
  21. 21.
    Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009;6:928–939.CrossRefPubMedGoogle Scholar
  22. 22.
    Gou Q, Liu L, Wang C, Wu Q, Sun L, Yang X, et al. Polymeric nanoassemblies entrapping curcumin overcome multidrug resistance in ovarian cancer. Colloid Surface B 2015;126:26–34.CrossRefGoogle Scholar
  23. 23.
    Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human nonsmall cell lung cancer A549 cell line. Acta Pharm Sin B 2015;5:554–563.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hu T, To KK, Wang L, Zhang L, Lu L, Shen J, et al. Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza. Phytomedicine 2014;21:1264–1272.CrossRefPubMedGoogle Scholar
  25. 25.
    Xia C, Bai X, Hou X, Gou X, Wang Y, Zeng H, et al. Cryptotanshinone reverses cisplatin resistance of human lung carcinoma A549 cells through down-regulating Nrf2 pathway. Cell Physiol Biochem 2015;37:816–824.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim MK, Park KS, Choo H, Chong Y. Quercetin-POM (pivaloxymethyl) conjugates: modulatory activity for P-glycoprotein-based multidrug resistance. Phytomedicine 2015;22:778–785.CrossRefPubMedGoogle Scholar
  27. 27.
    Yuan J, Wong IL, Jiang T, Wang SW, Liu T, Wen BJ, et al. Synthesis of methylated quercetin derivatives and their reversal activities on P-gp-and BCRP-mediated multidrug resistance tumour cells. Eur J Med Chem 2012;54:413–422.CrossRefPubMedGoogle Scholar
  28. 28.
    Yuan Z, Wang H, Hu Z, Huang Y, Yao F, Sun S, et al. Quercetin inhibits proliferation and drug resistance in KB/VCR oral cancer cells and enhances its sensitivity to vincristine. Nutr Cancer 2015;67:126–136.CrossRefPubMedGoogle Scholar
  29. 29.
    Wu JM, Chen Y, Chen JC, Lin TY, Tseng SH. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett 2010;287:187–195.CrossRefPubMedGoogle Scholar
  30. 30.
    Li D, Liu H, Liu Y, Zhang Q, Liu C, Zhao S. Design, synthesis and biological activities of tetrandrine and fangchinoline derivatives as antitumer agents. Bioorg Med Chem Lett 2017;27:533–536.CrossRefPubMedGoogle Scholar
  31. 31.
    Lan J, Ning W, Lan H, Liu Y, Ma X, Lou H, et al. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. Eur J Med Chem 2017;127:554–556.CrossRefPubMedGoogle Scholar
  32. 32.
    Lu Y, Li F, Xu T, Sun J. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-KB signaling. Int J Mol Med 2017;39:993–1000.CrossRefPubMedGoogle Scholar
  33. 33.
    Sun YF, Wink M. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine 2014;21:1110–1119.CrossRefPubMedGoogle Scholar
  34. 34.
    Guo L, Zhang H, Wang F, Liu P, Wang Y, Xia G, et al. Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system. Int J Nanomedicine 2015;10:4535–4547.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Li N, Wang DD, Ge GB, Wang XL, LiuY, Yang L. Ginsenoside metabolites inhibit P-glycoprotein in vitro and in situ using three absorption models. Planta Med 2014; 80:290–296.CrossRefPubMedGoogle Scholar
  36. 36.
    Jin J, Shahi S, Kang HK, Van Veen H, Fan TP. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Bioph Res Co 2006; 345:1308–1314.CrossRefGoogle Scholar
  37. 37.
    Zhou B, Xiao X, Xu L, Zhu L, Tan L, Tang H, et al. A dynamic study on reversal of multidrug resistance by ginsenoside Rh(2) in adriamycin-resistant human breast cancer MCF-7 cells. Talanta 2012;88:345–351.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang J, Zhou F, Wu X, Zhang X, Chen Y, Zha BS, et al. Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells. Br J Pharmacol 2012;165:120–134.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Wen X, Zhang HD, Zhao L, Yao YF, Zhao JH, Tang JH. Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer. Asian Pac J Cancer Prev 2015;16:1105–1109.CrossRefPubMedGoogle Scholar
  40. 40.
    Li Y, Zhou T, Ma C, Song W, Zhang J, Yu Z. Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. J Thorac Dis 2015;7:400–406.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhang Y, Liu X, Zuo T, Liu Y, Zhang JH. Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Med Oncol 2012;29:534–538.CrossRefPubMedGoogle Scholar
  42. 42.
    Wang S, Lei T, Man Z. The reversal effect and its mechanisms of tetramethylpyrazine on multidrug resistance in human bladder cancer. PLoS One 2016;11:e0157759.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 2014;1840:615–625.CrossRefPubMedGoogle Scholar
  44. 44.
    Wang L, Wang C, Jia Y, Liu Z, Shu X, Liu K. Resveratrol increases anti-proliferative activity of bestatin through downregulating P-glycoprotein expression via inhibiting PI3K/Akt/mTOR pathway in K562/ADR cells. J Cell Biochem 2016;117:1233–1239.CrossRefPubMedGoogle Scholar
  45. 45.
    Meng J, Guo F, Xu H, Liang W, Wang C, Yang XD. Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep 2016;6:22390.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL, Ren F, et al. Grape seed procyanidin reversal of P-glycoprotein associated multi-drug resistance via down-regulation of NFkappaB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One 2013;8:e71071.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Wesolowska O, Wisniewski J, Sroda-Pomianek K, Bielawska-Pohl A, Paprocka M, Dus D, et al. Multidrug resistance reversal and apoptosis induction in human colon cancer cells by some flavonoids present in citrus plants. J Nat Prod 2012;75:1896–1902.CrossRefPubMedGoogle Scholar
  48. 48.
    Kasaian J, Mosaffa F, Behravan J, Masullo M, Piacente S, Ghandadi M, et al. Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. Fitoterapia 2015;103:149–154.CrossRefPubMedGoogle Scholar
  49. 49.
    Eid SY, El-Readi MZ, Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABCtransporters. Phytomedicine 2012;19:977–987.CrossRefPubMedGoogle Scholar
  50. 50.
    Xu HB, Xu LZ, Li L, Fu J, Mao XP. Reversion of P-glycoprotein-mediated multidrug resistance by guggulsterone in multidrug-resistant human cancer cell lines. Eur J Pharmacol 2012;694:39–44.CrossRefPubMedGoogle Scholar
  51. 51.
    Fang S, Zhu W, Zhang Y, Shu Y, Liu P. Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-kappaB activation. Mol Med Rep 2012;5:351–356.PubMedGoogle Scholar
  52. 52.
    Yu F, Li K, Chen S, Liu Y, Li Y. Pseudolaric acid B circumvents multidrug resistance phenotype in human gastric cancer SGC7901/ADR cells by downregulating COX-2 and P-gp expression. Cell Biochem Biophys 2015;71:119–126.CrossRefPubMedGoogle Scholar
  53. 53.
    Roy A, Ernsting MJ, Undzys E, Li SD. A highly tumortargeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors. Biomaterials 2015;52:335–346.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Su S, Cheng X, Wink M. Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells. Phytomedicine 2015;22:301–307.CrossRefPubMedGoogle Scholar
  55. 55.
    Sui H, Zhu HR, Wu J, Nikitin AY, Cai JF, Fan ZZ, et al. Effects of Jianpi Jiedu Recipe on reversion of P-glycoproteinmediated multidrug resistance through COX-2 pathway in colorectal cancer. Chin J Integr Med 2014;20:610–617.CrossRefPubMedGoogle Scholar
  56. 56.
    Li WB, Li Y, Yu C, He YM. Reversal of multidrug resistance by the Chinese medicine Yiqi Jianpi Huaji Decoction and the mechanism of action in human gastric cancer SGC7901/VCR cells. Evid Based Complement Alternat Med 2015;2015:390812.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Cai S, Zhang X, Chen Z, Kong L, Wang S. Medicated serum prepared with Chinese herbal medicine Zhizhen Recipe down-regulates activity of nuclear factor-kB and expression of P-glycoprotein in human colorectal cancer multidrug-resistant cell line HCT-8/VCR. J Chin Integr Med (Chin) 2011;9:1353–1359.CrossRefGoogle Scholar
  58. 58.
    Shi JP, Li SX, Ma ZL, Gao AL, Song YJ, Zhang H. Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB/c mice. Chin J Integr Med 2015;22:925–931.CrossRefPubMedGoogle Scholar
  59. 59.
    Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res 2014;58:7–21.CrossRefPubMedGoogle Scholar
  60. 60.
    Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M. The dark side of curcumin. Int J Cancer 2010;126:1771–1775.PubMedGoogle Scholar
  61. 61.
    Lonare M, Kumar M, Raut S, More A, Doltade S, Badgujar P, et al. Evaluation of ameliorative effect of curcumin on imidacloprid-induced male reproductive toxicity in Wistar rats. Environ Toxicol 2016;31:1250–1263.CrossRefPubMedGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2018

Authors and Affiliations

  • Huan-dong Zhao
    • 1
    • 4
  • Hong-juan Xie
    • 2
  • Jian Li
    • 1
  • Cai-ping Ren
    • 3
  • Yu-xiang Chen
    • 4
  1. 1.Key Laboratory of Nanobiological Technology of Chinese Ministry of Health, Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Department of Pharmacy, Tongren HospitalShanghai Jiaotong University, School of MedicineShanghaiChina
  3. 3.Cancer Research Institute, Collaborative Innovation Center for Cancer Medicine, Key Laboratory for Carcinogenesis of Chinese Ministry of Health, School of Basic Medical ScienceCentral South UniversityChangshaChina
  4. 4.School of PharmacyCentral South UniversityChangshaChina

Personalised recommendations